Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
ACADIA Pharmaceuticals (NASDAQ:ACAD) Inc. shares have reached a 52-week low, dipping to $14.14, as the company navigates through a tumultuous market period. According to InvestingPro analysis, the stock's RSI indicates oversold conditions, while the company maintains strong fundamentals with a healthy current ratio of 2.38 and more cash than debt on its balance sheet. This latest price point reflects a significant downturn from previous valuations, marking a challenging phase for the biopharmaceutical firm. Over the past year, ACADIA's stock has experienced a notable decline, with a 1-year change showing a decrease of -21.76%. Despite the price decline, the company achieved impressive revenue growth of 31.85% and maintains profitability with a P/E ratio of 10.46. Investors are closely monitoring the company's performance and potential market catalysts that may influence its stock trajectory in the upcoming quarters. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of ACADIA's market position.
In other recent news, Acadia Pharmaceuticals reported a 12% year-over-year increase in fourth-quarter 2024 revenue, reaching $259.6 million. The company's total revenue for 2024 amounted to $957.8 million, marking a 32% rise from the previous year. Acadia's DAYBUE sales surged by 97% in 2024, contributing significantly to this growth. Looking ahead, the company projects 2025 revenue to be between $1.03 billion and $1.095 billion, with expectations for DAYBUE sales to reach $380 million to $450 million.
In terms of analyst activity, TD Cowen maintained a Buy rating on Acadia Pharmaceuticals with a price target of $35, citing strong fourth-quarter earnings that surpassed expectations. Meanwhile, Citizens JMP adjusted its price target from $39 to $37 while keeping a Market Outperform rating, reflecting moderated growth projections for DAYBUE in 2025. Acadia also announced inducement awards for new employees under its 2024 Inducement Plan, granting stock options and restricted stock units. Furthermore, the company published a study confirming the safety of DAYBUE for young Rett syndrome patients, which supported its FDA approval for this age group.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.